-
Product Insights
NewHyaluronic Acid Fillers Pipeline by Development Stages, Segments, Region and Countries, Regulatory Path and Key Companies
Hyaluronic Acid Fillers Pipeline Market Report Overview Hyaluronic Acid (HA) is a glycosaminoglycan disaccharide, which exists naturally in the body. Approximately 50% of the total HA is found in the skin. Injections of HA are used for reducing wrinkles in the face and for soft tissue augmentation. The hyaluronic acid fillers pipeline market research report provides a comprehensive understanding of the pipeline products along with their comparative analysis at various stages of development. The report also includes information about the...
-
Innovation Ranking
NewInnovation Ranking – ImmunoGen Inc
ImmunoGen Inc (ImmunoGen) is a clinical-stage biotechnology company that focuses on the development of novel antibody-drug conjugates (ADCs) that facilitate targeted therapies for the treatment of cancer. Its pipeline product candidates include mirvetuximab soravtansine for the treatment of platinum-resistant ovarian cancer; IMGN632 for AML, and pivekimab sunirine for blastic plasmacytoid dendritic cell neoplasm (BPDCN); IMGC936, the company’s product candidate for a range of solid tumors; and IMGN151, its next-generation anti-FRa candidate in the preclinical development stage. ImmunoGen incorporates its proprietary...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – IMGN-151 in Fallopian Tube Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IMGN-151 in Fallopian Tube Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. IMGN-151 in Fallopian Tube Cancer Drug Details: IMGN-151 is under development...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – IMGN-151 in Peritoneal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IMGN-151 in Peritoneal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. IMGN-151 in Peritoneal Cancer Drug Details: IMGN-151 is under development for the...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – IMGN-151 in Epithelial Ovarian Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IMGN-151 in Epithelial Ovarian Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. IMGN-151 in Epithelial Ovarian Cancer Drug Details: IMGN-151 is under development...
-
Product Insights
NewNet Present Value Model: ImmunoGen Inc’s Pivekimab sunirine
Empower your strategies with our Net Present Value Model: ImmunoGen Inc's Pivekimab sunirine report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – IMGN-151 in Endometrial Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IMGN-151 in Endometrial Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. IMGN-151 in Endometrial Cancer Drug Details: IMGN-151 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BOLD-100 in Colon Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BOLD-100 in Colon Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BOLD-100 in Colon Cancer Drug Details: BOLD-100 (IT-139, NKP-1339) is under development...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Galinpepimut-S in Multiple Myeloma (Kahler Disease)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Galinpepimut-S in Multiple Myeloma (Kahler Disease) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Galinpepimut-S in Multiple Myeloma (Kahler Disease) Drug Details: Galinpepimut-S is...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Enristomig in Adenocarcinoma Of The Gastroesophageal Junction
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Enristomig in Adenocarcinoma Of The Gastroesophageal Junction report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Enristomig in Adenocarcinoma Of The Gastroesophageal Junction Drug Details:...